Launches Indigo® System Lightning™ 12 in
U.S.
Appoints Corey L. Teigen, M.D., as Chief
Scientific Officer and James F. Benenati, M.D., FSIR, as Chief
Medical Officer
Penumbra, Inc. (NYSE: PEN), a global healthcare company focused
on innovative therapies, today announced its next phase for
vascular franchise growth with U.S. commercial availability of the
Indigo® System Lightning™ 12 and the appointments of Corey L.
Teigen, M.D., to chief scientific officer and James F. Benenati,
M.D., FSIR, to chief medical officer, two newly created positions.
Innovating the Indigo System peripheral thrombectomy technology is
a key part of the company’s overall growth plan to continue
momentum in its fast-growing vascular franchise.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200714005400/en/
Lightning™ 12 – Intelligent Aspiration
Powered by Penumbra ENGINE™ (Photo: Business Wire)
Indigo System Lighting 12: The Most Advanced Clot Removal
Technology
The Indigo System Lightning 12 is the company’s next generation
aspiration system for peripheral thrombectomy. Lightning 12
combines the new Indigo System CAT™12 Aspiration Catheter with
Lightning™ Intelligent Aspiration, enabling physicians to focus on
optimizing thrombus removal using the system’s unique clot
detection mechanism. CAT12 is a large-lumen aspiration catheter
that incorporates novel laser-cut hypotube-based catheter
engineering to provide advanced deliverability and torqueability
within the body. This combination of intelligent aspiration and
large-lumen catheter engineering makes Lightning 12 Penumbra’s most
advanced clot removal technology.
“Penumbra continues to lead the field of clot management by
bringing highly innovative technology to address the challenges
that we as physicians face while caring for our patients,” said
Frank Arko, M.D., chief, Division of Vascular and Endovascular
Surgery, Sanger Heart and Vascular Institute, North Carolina. “When
dealing with thrombus, we have learned that it is the combination
of the catheter along with powered aspiration that yields the most
effective results. Lightning 12 with Intelligent Aspiration is a
giant leap forward for the field of thrombectomy, and we have been
very impressed with the early results at Sanger.”
“The simplicity of Lightning Intelligent Aspiration combined
with the significant advancements in catheter engineering will
enable us as physicians to get closer to our thrombus removal goal
in a safe manner, as well as our goal of improving clinical
outcomes for our patients,” said Patrick Muck, M.D., chief,
Vascular Surgery, Good Samaritan Hospital, Ohio.
“Lightning 12 provides physicians with an integrated system that
not only removes large amounts of thrombus but also detects and
manages clot removal,” said Jay Mathews, M.D., interventional
cardiologist, Manatee Memorial Hospital, Florida. “This is a very
important advancement for the field of thrombus management, and our
initial experience at Manatee Memorial with this technology shows
us that we are now closer to single-setting care for our
patients.”
New Leadership Appointments
Penumbra also announced appointments for two newly created
positions: Corey L. Teigen, M.D., as chief scientific officer and
James F. Benenati, M.D., FSIR, as chief medical officer.
Dr. Teigen joins immediately as CSO and will contribute his
extensive scientific and clinical expertise to ongoing and future
research and development efforts.
“In my radiology practice, I’ve seen firsthand the challenges
medical practitioners face while treating difficult medical
conditions,” Dr. Teigen said. “At Penumbra, I have a profound
opportunity to change the course of healthcare delivery for people
living with vascular disease. I feel privileged to join Penumbra’s
unparalleled group of talented engineers and leaders, and I look
forward to contributing my scientific knowledge to help solve
challenging medical problems.”
Dr. Benenati will join Penumbra on September 1, 2020, as CMO,
and will contribute to clinical and medical affairs strategies and
advise upon global commercialization and market development
activities.
“I’m excited to join Penumbra at this very important time for
the company, where it’s poised for growth, as it moves into the
next generation of intelligent clot removal and expand into
rehabilitation with the recent launch of the REAL system,” Dr.
Benenati said. “Penumbra has changed the landscape of healthcare by
providing truly innovative solutions for a wide realm of medical
challenges. In this next phase, Penumbra is set to broaden its
reach on a global scale, and I am thrilled to join this excellent
team and help accelerate the impact of its products.”
“I am thrilled we are bringing Lightning 12, the most advanced
technology for aspiration thrombectomy, to the peripheral
interventional community,” said Adam Elsesser, president and chief
executive officer, Penumbra. “It is an ideal time for us to welcome
Corey and Jim to Penumbra’s leadership team as we progress into our
next phase of growth. Their career-long focus on patient care and
their innovative mindset are a perfect fit with our vision and
culture, which is dedicated to making a fundamental difference in
patients’ lives.”
About Corey L. Teigen, M.D.
Corey L. Teigen, M.D., is a board certified vascular and
interventional radiologist. He is also a researcher and developer
of interventional devices. Dr. Teigen received his medical degree
from Johns Hopkins University School of Medicine with distinction
and did his radiology residency at the Mayo Clinic Rochester,
Minnesota. He completed his fellowship at the Miami Cardiac and
Vascular Institute, Miami, Florida. He served as Chairman of
Interventional Radiology at Sanford Health, Fargo, North Dakota for
25 years. Dr. Teigen has authored numerous publications and has
been involved in the development of multiple interventional devices
for the treatment of vascular and other diseases. He has presented
more than 100 professional talks sharing lessons learned and
successes realized over his 30-year career in the practice of
Interventional Radiology. Dr. Teigen’s research has focused on
multiple areas including development of the Cordis Incraft stent
graft for the endovascular repair of abdominal aneurysm. He has
also been involved in the development of intravascular stents,
balloons, liquid and coil embolics, inferior vena cava filters, and
thrombectomy devices. He has served on the Peripheral Vascular
Committee of SIR and was Co-director of the Sanford Health Vascular
Institute.
About James F. Benenati, M.D., FSIR
James F. Benenati, M.D., FSIR, is a board certified vascular and
interventional radiologist. Prior to joining Penumbra, Dr. Benenati
practiced interventional radiology at the Miami Cardiac &
Vascular Institute at Baptist Hospital in Miami for 30 years, where
he has served in multiple positions, including medical director of
the noninvasive vascular laboratory and fellowship program
director. He is the vice chairman of the department of
interventional radiology and clinical professor of radiology at the
Florida International University Herbert Wertheim College of
Medicine, Miami. He is also a Collaborative Professor of Radiology
at the University of South Florida Morsani College of Medicine. He
is past President of the Society of Interventional Radiology (SIR
2011) and past Annual Meeting Chairman for the SIR Annual Meeting
in 2005. He has received the highest awards given by the SIR
including the SIR Gold Medal and the Charles T. Dotter Award. Dr.
Benenati is the founding Medical Director of the Nova Southeastern
University Health Sciences BS/ RVT program. He served as President
of the Vascular Division for the Intersocietal Accreditation
Committee (IAC) and has served for over a decade on the IAC
Vascular Testing Board. Over the course of his career, Dr. Benenati
has authored more than 120 scientific publications, published
numerous book chapters and edited journals and textbooks in
interventional radiology. He has lectured nationally and
internationally, and has been a program director of the
International Symposium on Endovascular Technology (ISET) for 30
years. His undergraduate education was at the University of Notre
Dame, he attended medical school at the University of South Florida
College of Medicine from 1980-1984, he completed a diagnostic
radiology residency at Indiana University School of Medicine in
1988, and he completed a fellowship in Cardiovascular and
Interventional Radiology at the Johns Hopkins University School of
Medicine in 1989.
About Indigo System
The latest generation of Penumbra’s continuous aspiration
thrombectomy system features Indigo System Lightning 12 which
combines the new Indigo System CAT 12 Aspiration Catheter with
Lightning Intelligent Aspiration powered by Penumbra ENGINE,
enabling physicians to focus on optimizing thrombus removal using
the system’s unique clot detection mechanism. The Indigo System’s
proprietary Separator technology, Separator 12 is also available
with Lightning 12 and is designed to enable unobstructed aspiration
for the duration of the procedure. Lightning 12 and Separator 12
are designed for the removal of fresh, soft emboli and thrombi from
the peripheral arterial and venous systems.
In addition to Lightning 12, the Indigo System also now includes
Lightning 8 which combines the Indigo System CAT 8 Aspiration
Catheter with Lightning Intelligent Aspiration for the removal of
fresh, soft emboli and thrombi from the peripheral arterial and
venous systems, and for the treatment of pulmonary embolism.
Lightning 12 and Lightning 8 expand the already broad offering of
CAT8, CATD, CAT6, CAT5, and CAT3 and are paired with Penumbra
ENGINE, the company’s proprietary continuous, mechanical vacuum
aspiration pump.
Important Safety Information
Additional information about Penumbra’s products can be located
on Penumbra’s website at
http://www.penumbrainc.com/healthcare-professionals. Prior to use,
please refer to Instructions for Use for complete product
indications, contraindications, warnings, precautions, potential
adverse events and detailed instructions for use.
About Penumbra
Penumbra, Inc., headquartered in Alameda, California, is a
global healthcare company focused on innovative therapies. Penumbra
designs, develops, manufactures and markets novel products and has
a broad portfolio that addresses challenging medical conditions in
markets with significant unmet need. Penumbra sells its products to
hospitals and healthcare providers primarily through its direct
sales organization in the U.S., most of Europe, Canada and
Australia, and through distributors in select international
markets. Penumbra, the Penumbra P logo, Indigo, CAT, Separator,
Lightning, Penumbra ENGINE and REAL are trademarks of Penumbra,
Inc. For more information, visit www.penumbrainc.com and connect on
Twitter and LinkedIn.
Forward-Looking Statements
Except for historical information, certain statements in this
press release are forward-looking in nature and are subject to
risks, uncertainties and assumptions about us. Our business and
operations are subject to a variety of risks and uncertainties and,
consequently, actual results may differ materially from those
projected by any forward-looking statements. Factors that could
cause actual results to differ from those projected include, but
are not limited to: the impact of the COVID-19 pandemic on our
business, results of operations and financial condition; failure to
sustain or grow profitability or generate positive cash flows;
failure to effectively introduce and market new products; delays in
product introductions; significant competition; inability to
further penetrate our current customer base, expand our user base
and increase the frequency of use of our products by our customers;
inability to achieve or maintain satisfactory pricing and margins;
manufacturing difficulties; permanent write-downs or write-offs of
our inventory; product defects or failures; unfavorable outcomes in
clinical trials; inability to maintain our culture as we grow;
fluctuations in foreign currency exchange rates; and potential
adverse regulatory actions. These risks and uncertainties, as well
as others, are discussed in greater detail in our filings with the
Securities and Exchange Commission, including our Annual Report on
Form 10-K for the year ended December 31, 2019 filed with the SEC
on February 26, 2020, and our Quarterly Reports on Form 10-Q. There
may be additional risks of which we are not presently aware or that
we currently believe are immaterial which could have an adverse
impact on our business. Any forward-looking statements are based on
our current expectations, estimates and assumptions regarding
future events and are applicable only as of the dates of such
statements. We make no commitment to revise or update any
forward-looking statements in order to reflect events or
circumstances that may change.
Source: Penumbra, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200714005400/en/
Investor Relations: Penumbra, Inc. investors@penumbrainc.com
510-995-2461
Media Relations: Joni Ramirez Merryman Communications
joni@merrymancommunications.com 323-532-0746
Penumbra (NYSE:PEN)
Historical Stock Chart
From Apr 2024 to May 2024
Penumbra (NYSE:PEN)
Historical Stock Chart
From May 2023 to May 2024